Mircera (methoxy polyethylene glycol-epoetin beta)

Information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor.

Mircera is a long-acting erythropoietin stimulating agent (ESA) used for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients.1 It is the first Continuous Erythropoietin Receptor Activator (C.E.R.A.).2 It works like the human protein erythropoietin to help the body make more red blood cells and is used to reduce or avoid the need for red blood cell transfusion.1 The distinct molecular interaction of Mircera is believed to play an important role in providing targeted, stable and sustained control of anaemia.2

 

In Bangladesh Mircera is approved for the following indication.3

  • MIRCERA is indicated for the treatment of anemia associated with chronic kidney disease (CKD) including patients on dialysis and patients not on dialysis.

 

For more disease and medicine related queries you may discuss with your physician.

 

In Bangladesh Mircera is available as

  • Pre-filled syringe containing 50 µg in 0.3 ml
  • Pre-filled syringe containing 75 µg in 0.3 ml
  • Pre-filled syringe containing 100 µg in 0.3 ml

 

References

1. Global Website: Investors. Roche enters into exclusive license agreement with Galenica for the commercialisation of Mircera in the United States. (2015, May 28). [Internet; cited 2018, November 11]. Retrieved from https://www.roche.com/investors/updates/inv-update-2015-05-28.htm

2. Global Website: Investors. Mircera: first drug to correct anaemia in all chronic kidney disease patients with a simple twice-monthly dosing schedule. (2006, November 20). [Internet; cited 2018, November 11]. Retrieved from https://www.roche.com/investors/updates/inv-update-2006-11-20.htm

3. Mircera Product Information _ FE-English Ro 050-3821 _ May 2015